Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
LabConnect has launched a new digital platform that enables research sites to scan, record, and transmit participant sample data directly from mobile devices.
read more
Torqur AG, a clinical-stage biotechnology company advancing treatments for oncology and dermatology, and Lonza, a contract development and manufacturing organizations\ (CDMOs), announced an agreement for the clinical supply of bimiralisib, an ...
read more
Samsung Biologics announced the completion of its acquisition of a manufacturing facility in Rockville, Maryland from GSK, establishing the company’s first manufacturing presence in the United States.
read more
Wednesday, April 01, 2026
Sygnature Discovery announced the appointment of Susanne Back as Head of In Vivo Pharmacology, further strengthening its bioscience leadership and reinforcing its commitment to delivering high-quality, integrated drug discovery solutions for ...
read more
Wednesday, April 01, 2026
Adragos Pharma announced that it completed the acquisition of a commercial-scale sterile fill-finish facility in Maisons-Alfort, France, from Sanofi.
read more
Wednesday, April 01, 2026
NJ Bio and Ajinomoto Bio Pharma Services announced a research collaboration to expand access to AJICAP™, Aji Bio Pharma's site specific conjugation platform for NJ Bio's discovery stage and early development clients.
read more
CellCarta and Pillar Biosciences announced a global multi-year strategic partnership to broaden access to fast, operationally streamlined next-generation sequencing (NGS) tumor profiling for biopharma sponsors and clinical research partners worldwide...
read more
Lonza announced the launch of its Media Development Lab at its Singapore site. The offering aims to support bioprocessing customers in optimizing their media formulations and facilitating a smooth transition to GMP manufacturing, helping reduce scale...
read more
Perceptive Discovery announced a major expansion of its in vitro laboratory capabilities at its Needham, Massachusetts facility. This strategic investment significantly enhances the company's ability to support preclinical oncology research, ...
read more
Azenta announced the appointment of Trey Martin as President of its Multiomics business, effective April 6, 2026. In this role, Mr. Martin will lead the Multiomics organization and report to John Marotta, Azenta's President and Chief Executive ...
read more
Ofichem has unified its business divisions under a single brand identity, announcing that all operations will now trade under the Ofichem name. The move consolidates several long-standing brands — including Ofichem BV, Ofipharma, Ofimedicine, ...
read more
Altruist Biologics, an Innovent Biologics subsidiary and contract development and manufacturing organization (CDMO), announced that its Hangzhou facility was granted the Drug Product Manufacturing License (C Certificate) from the Chinese National ...
read more
Scinai Immunotherapeutics has completed a strategic corporate reorganization that establishes a dedicated contract development and manufacturing organization (CDMO) subsidiary and a leaner research and development operation.
read more
Cartherics Pty Ltd and Catalent have signed an amended commercial license agreement enabling the use of a Catalent cGMP compliant induced pluripotent stem cells (iPSC) line for the manufacture and commercialization of Cartherics’ iPSC-derived ...
read more
Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted radiotherapy (TRT), supporting the advancement of discovery and preclinical programs.
read more